Key clinical point: Chronic migraine patients who achieved early reversal to episodic migraine are likely to have persistent reversion with long-term erenumab treatment.
Major finding: At 12 weeks, 54.1% (95% confidence interval [CI], 46.6%-61.6%) of patients showed reversal to episodic migraine. Continued treatment with erenumab showed a long-term persistent reversion in 96.8% (95% CI, 91.1%-99.3%) of patients at week 64.
Study details: Data on 181 migraine patients come from a post hoc analysis of a 12-week randomized double-blind trial and a 52-week open-label extension.
Disclosures: The study was funded by Amgen Inc. The authors reported ties with various institutions and/or pharmaceutical companies. F Zhang, GA Rippon, S Cheng, and DD Mikol are employed by and own stock in Amgen.
Source: Lipton RB et al. Cephalalgia. 2020 Dec 3. doi: 10.1177/0333102420973994 .